Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HTR3A | P46098 | 7/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HTR6 | P50406 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PLK1 | P53350 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17170611 | 0.84 | ALDH1A1 (0.56) | ALDH1A1HTR3ALMNASMN1; SMN2HTR6 | |
| SCHEMBL17176486 | 0.84 | LMNA (0.65) | ALDH1A1HTR3ALMNASMN1; SMN2HTR6 | |
| SCHEMBL17170580 | 0.83 | ALDH1A1 (0.55) | ALDH1A1HTR3ALMNASMN1; SMN2HTR6 | |
| SCHEMBL17170673 | 0.82 | ALDH1A1 (0.57) | ALDH1A1HTR3ALMNASMN1; SMN2HTR6 | |
| SCHEMBL17170675 | 0.80 | ALDH1A1 (0.54) | ALDH1A1HTR3ALMNASMN1; SMN2HTR6 | |
| SCHEMBL17321400 | 0.74 | ALDH1A1 (0.61) | ALDH1A1LMNASMN1; SMN2TSHRHTT | |
| SCHEMBL17885855 | 0.74 | ALDH1A1 (0.65) | ALDH1A1LMNASMN1; SMN2TSHRHTT | |
| SCHEMBL26054015 | 0.71 | CNR1 (0.65) | ALDH1A1LMNATSHRHTT | |
| SCHEMBL17170733 | 0.71 | NR4A2 (0.64) | ALDH1A1HTR3ALMNASMN1; SMN2TSHR | |
| SCHEMBL17321387 | 0.71 | ALDH1A1 (0.74) | ALDH1A1LMNASMN1; SMN2TSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072758-A1 | 5HT3 RECEPTOR ANTAGONISTS | TAKEDA CALIFORNIA, INC. | 2018-03-15 | — | — | US | disclosed |
| US-9695195-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-07-04 | — | — | US | disclosed |
| US-9303045-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-04-05 | — | — | US | disclosed |
| US-20150291624-A1 | 5-HT3 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291624-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR5A, HTR3B | ALDH1A1 1649/4885HTR3A 1/4885LMNA 3559/4885 |
| US-20180072758-A1 | 5HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR3B, HTR5A | ALDH1A1 1516/4885HTR3A 1/4885LMNA 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.